JZYY(SH:600750)2020-10-27 16:00Financial Performance - Net profit attributable to shareholders of the listed company was ¥398,040,367.58, reflecting a year-on-year increase of 4.30%[17] - Operating income for the first nine months was ¥1,735,158,093.44, up 1.85% from the same period last year[17] - The net cash flow from operating activities for the first nine months was ¥714,502,701.39, an increase of 11.35% year-on-year[17] - Total operating revenue for Q3 2020 was CNY 576,696,483, an increase from CNY 562,694,201 in Q3 2019, representing a growth of 2.0%[72] - Net profit for Q3 2020 was CNY 131,840,980.81, slightly down from CNY 133,499,477.02 in Q3 2019, a decrease of 1.2%[75] - Total comprehensive income attributable to the parent company for the first three quarters of 2020 was approximately ¥398.04 million, up from ¥381.64 million in the same period of 2019[77] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,793,102,378.24, an increase of 0.71% compared to the end of the previous year[17] - Current liabilities decreased to ¥543,858,700.26 from ¥748,912,845.10, a reduction of approximately 27.4%[61] - Total liabilities decreased to ¥621,326,102.28 from ¥834,837,147.96, a reduction of approximately 25.6%[63] - Total equity increased to ¥4,171,776,275.96 from ¥3,924,356,609.29, reflecting a growth of about 6.3%[63] Revenue Breakdown - Revenue from over-the-counter drugs was ¥1,356,244,387.59, with a year-on-year increase of 2.52%[23] - Revenue from prescription drugs was ¥253,000,999.78, showing a year-on-year decrease of 9.89%[23] - Revenue from the East China region was ¥514,027,424.91, an increase of 7.16% compared to the previous year[24] Cash Flow and Investments - The company's cash and cash equivalents at the end of the period amounted to 291 million RMB, a decrease of 637 million RMB or 68.65% compared to the end of the previous year, primarily due to the investment in bank principal-protected financial products[27] - The net cash flow from investing activities was -1.188 billion RMB, an increase in outflow of 652 million RMB compared to the same period last year, primarily due to the purchase of bank financial products[29] - The net cash flow from operating activities for Q3 2020 was CNY 715,185,378.15, an increase from CNY 599,368,225.16 in Q3 2019, reflecting a growth of about 19.4%[89] Research and Development - Research and development expenses for Q3 2020 amounted to CNY 10,932,375.89, up from CNY 9,840,382.47 in Q3 2019, indicating an increase of 11.1%[72] - Research and development expenses increased to ¥10.93 million in Q3 2020, up 11.1% from ¥9.84 million in Q3 2019[80] Shareholder Information - The company reported a total of 44,593 shareholders at the end of the reporting period[24] - The company has no related party or concerted action relationships with the top ten shareholders, with the controlling shareholder being China Resources Jiangzhong Pharmaceutical Group[27] Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[75]